Oral vinorelbine (NVBO) in combination with trastuzumab (HER) in metastatic breast cancer (MBC): Data on efficacy and safety when administered in first- or second-line treatment
- Resource Type
- Authors
- F. Carabantes; I. Blancas; F. Pérez; E. Polo Marques; M. Corral; E. M. Ciruelos Gil; P. Bueso; Jose Juan Illarramendi
- Source
- Journal of Clinical Oncology. 28:e11508-e11508
- Subject
- Oncology
Cancer Research
medicine.medical_specialty
Second line treatment
business.industry
Vinorelbine
medicine.disease
Metastatic breast cancer
Surgery
stomatognathic diseases
Regimen
Trastuzumab
Internal medicine
medicine
skin and connective tissue diseases
business
neoplasms
medicine.drug
- Language
- ISSN
- 1527-7755
0732-183X
e11508 Background: Vinorelbine plus HER is an active and well-tolerated regimen in HER2-overexpressing MBC. When HER is administered every 3 weeks, the use of oral vinorelbine can increase the pati...